Register a trial

Please note that the ANZCTR website will be unavailable from 1:00pm until 2:00pm (AEST) on Thursday 10th of April for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.


The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04494789




Registration number
NCT04494789
Ethics application status
Date submitted
19/07/2020
Date registered
31/07/2020

Titles & IDs
Public title
Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS
Scientific title
A Phase II Open Label Randomised Controlled Clinical Trial of Different Dosing Regimens of Fludrocortisone in Septic Shock With Assessment of Temporal Changes in Hormonal, Inflammatory, and Genetic Markers of Vascular Responsiveness
Secondary ID [1] 0 0
GI-CC35837377
Universal Trial Number (UTN)
Trial acronym
FluDReSS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Critically Ill 0 0
Septic Shock 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fludrocortisone Acetate
Treatment: Drugs - Fludrocortisone Acetate
Treatment: Drugs - Fludrocortisone Acetate
Other interventions - Standard Therapy

Active comparator: Fludrocortisone dosing regime: 24hrs - Receive 50mcg doses of fludrocortisone every 24hrs

Active comparator: Fludrocortisone dosing regime: 12hrs - Receive 50mcg doses of fludrocortisone every 12hrs

Active comparator: Fludrocortisone dosing regime: 6hrs - Receive 50mcg doses of fludrocortisone every 6hrs

Placebo comparator: Control Arm - Receives standard treatment without fludrocortisone dosing regime


Treatment: Drugs: Fludrocortisone Acetate
50mcg

Treatment: Drugs: Fludrocortisone Acetate
100mcg

Treatment: Drugs: Fludrocortisone Acetate
200mcg

Other interventions: Standard Therapy
NO Fludrocortisone
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to resolution of shock by Intervention group allocation
Timepoint [1] 0 0
7 DAYS
Primary outcome [2] 0 0
Time to resolution of shock and Fludrocortisone Levels
Timepoint [2] 0 0
7 days
Primary outcome [3] 0 0
Vasopressor Responsiveness by Intervention group allocation
Timepoint [3] 0 0
7 days
Primary outcome [4] 0 0
Vasopressor Responsiveness and Fludrocortisone Levels
Timepoint [4] 0 0
7 days
Secondary outcome [1] 0 0
Recurrence of shock
Timepoint [1] 0 0
censored at day 28
Secondary outcome [2] 0 0
Ventilation free days
Timepoint [2] 0 0
censored at day 28
Secondary outcome [3] 0 0
ICU and hospital length of Stay
Timepoint [3] 0 0
censored at day 28
Secondary outcome [4] 0 0
ICU and hospital mortality
Timepoint [4] 0 0
censored at day 28
Secondary outcome [5] 0 0
Delta SOFA Score
Timepoint [5] 0 0
censored at day 28
Secondary outcome [6] 0 0
Maximal SOFA score
Timepoint [6] 0 0
censored at day 28
Secondary outcome [7] 0 0
Superinfection
Timepoint [7] 0 0
censored at day 28

Eligibility
Key inclusion criteria
1. Aged 18 years or older
2. Documented site, or strong suspicion of infection with 2 of the 4 clinical signs of inflammation:

1. Core temperature > 38oC or < 35oC
2. Heart rate > 90bpm
3. Respiratory rate > 20bpm, or PaCO2 < 32mmHg, or mechanical ventilation
4. White cell count > 12 x 109/L or < 4 x 109/L or > 10% immature neutrophils
3. Being treated with Hydrocortisone at a daily dose of 200mg / day as adjunctive treatment for sepsis
4. Being treated with mechanical ventilation at the time of randomisation (includes mask BiPAP/CPAP)
5. Being treated with continuous vasopressors or inotropes to maintain a systolic blood pressure > 90mmHg, or mean arterial pressure > 60mmHg or a MAP target set by the treating clinician for maintaining perfusion
6. Administration of vasopressors or inotropes for > 4 hours and present at time of randomisation
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Met all inclusion criteria more than 24 hours ago
2. Patients taking long term corticosteroids or fludrocortisone
3. Patients with systemic fungal infection
4. Death is deemed inevitable or imminent during this admission and either the attending physician, patient or surrogate legal decision maker is not committed to active treatment
5. Patient unable to receive enteral medication
6. Death from underlying disease likely within 90 days
7. Patient has been previously enrolled in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/02/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/06/2023
Sample size
Target
Accrual to date
Final
155
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Blacktown Hospital - Sydney
Recruitment hospital [2] 0 0
Royal North Shore Hospital - Sydney
Recruitment hospital [3] 0 0
Royal Brisbane Women's Hospital - Brisbane
Recruitment hospital [4] 0 0
Wesley Hospital - Brisbane
Recruitment hospital [5] 0 0
Gold Coast University Hospital - Gold Coast
Recruitment hospital [6] 0 0
Mater Misericordiae - Raymond Terrace
Recruitment hospital [7] 0 0
Princess Alexandra Hospiital - Woolloongabba
Recruitment hospital [8] 0 0
Queen Elizabeth II Hospital - Adelaide
Recruitment hospital [9] 0 0
Austin Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Sydney
Recruitment postcode(s) [2] 0 0
- Brisbane
Recruitment postcode(s) [3] 0 0
- Gold Coast
Recruitment postcode(s) [4] 0 0
4101 - Raymond Terrace
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
- Adelaide
Recruitment postcode(s) [7] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
The George Institute
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
James Walsham, MB ChB, MRCP, FCICM.
Address 0 0
Princess Alexandra Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04494789